6,999 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by Stifel Financial Corp

Stifel Financial Corp bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,999 shares of the specialty pharmaceutical company’s stock, valued at approximately $418,000.

A number of other hedge funds have also recently made changes to their positions in the company. Global Alpha Capital Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in ANI Pharmaceuticals during the 2nd quarter worth $228,000. Thompson Siegel & Walmsley LLC lifted its holdings in ANI Pharmaceuticals by 17.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after buying an additional 34,416 shares during the period. Thrivent Financial for Lutherans lifted its holdings in ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after buying an additional 299 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of ANI Pharmaceuticals by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company’s stock valued at $9,985,000 after buying an additional 20,900 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $54.41 on Friday. The firm has a 50 day moving average of $57.48 and a 200-day moving average of $59.68. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -98.93 and a beta of 0.73. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period last year, the company posted $1.05 earnings per share. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Finally, Raymond James boosted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,231 shares of company stock worth $2,434,286. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.